GERN Geron Corporation

-0.06  -4%
Previous Close 1.52
Open 1.54
Price To Book 1.6
Market Cap 272,313,429
Shares 186,516,047
Volume 1,245,117
Short Ratio
Av. Daily Volume 1,764,856

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to commence August 2019.
Imetelstat - IMerge Study
Myelodysplastic syndromes
Janssen noted September 27, 2018 not to continue collaboration. Decision on future development due by 3Q 2019.
Imetelstat - IMbarkStudy

Latest News

  1. Such Is Life: How Geron (NASDAQ:GERN) Shareholders Saw Their Shares Drop 58%
  2. Geron Appoints Vice President, Human Resources
  3. Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress
  4. Geron to Webcast KOL Event on June 25, 2019
  5. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
  6. Why Is Geron (GERN) Down 22% Since Last Earnings Report?
  7. Geron Stock Up More Than 50% in 2019 So Far: Here's Why
  8. Did Geron's Big Announcement Just Go Unnoticed?
  9. Geron Announces Two Presentations on Imetelstat at Upcoming European Hematology Association Annual Congress
  10. Geron Provides Imetelstat Program Update
  11. Geron Continues to Build Senior Leadership of Its Development Team
  12. Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up
  13. Geron: 1Q Earnings Snapshot
  14. Geron Corporation Reports First Quarter 2019 Financial Results
  15. Analysts Estimate Geron (GERN) to Report a Decline in Earnings: What to Look Out for
  16. Can We See Significant Institutional Ownership On The Geron Corporation (NASDAQ:GERN) Share Register?
  17. 3 Cancer Treatment Stocks to Buy in April
  18. Geron Expands Senior Leadership of Its Development Team
  19. Geron's Blood Cancer Candidate Creates Buying Opportunity, Needham Says In Upgrade
  20. BRIEF-China's Geron Says Controlling Shareholder Plans To Unload Up To 6 Pct Stake In The Company